1. Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations
- Author
-
Adriana Balduzzi, G. A. Amos Burke, Stephanie Mueller, Birgit Burkhardt, Lisa Lyngsie Hjalgrim, Kristin Koeppen, Andishe Attarbaschi, Edita Kabickova, Felix Niggli, Mara Andrés, Heidi Herbrueggen, Nathalie Garnier, Alina Fedorova, Jan Loeffen, E. Bubanska, Monika Csóka, Anne Uyttebroeck, Marta Pillon, Volkan Hazar, Veronique Minard-Colin, Jelena Lazic, Mary Taj, Karin Mellgren, Wilhelm Woessmann, Tomoo Osumi, Anna Pieczonka, Alan K. S. Chiang, Jacek Wachowiak, Auke Beishuizen, Natalia Myakova, Martin Zimmermann, Svetlana Donska, Julia Palma, Jochen Buechner, Gergely Kriván, Jaime Verdu-Amoros, Burkhardt, Birgit [0000-0002-1151-829X], Taj, Mary [0000-0002-7107-618X], Osumi, Tomoo [0000-0001-5536-6788], Attarbaschi, Andishe [0000-0002-9285-6898], Chiang, Alan Kwok Shing [0000-0002-1089-5325], Wachowiak, Jacek [0000-0002-4680-603X], Uyttebroeck, Anne [0000-0001-5644-424X], Buechner, Jochen [0000-0001-5848-4501], Krivan, Gergely [0000-0003-4853-4354], Burke, GA Amos [0000-0003-2671-9972], Balduzzi, Adriana [0000-0002-5879-0610], Apollo - University of Cambridge Repository, Burkhardt, B, Taj, M, Garnier, N, Minard-Colin, V, Hazar, V, Mellgren, K, Osumi, T, Fedorova, A, Myakova, N, Verdu-Amoros, J, Andres, M, Kabickova, E, Attarbaschi, A, Chiang, A, Bubanska, E, Donska, S, Hjalgrim, L, Wachowiak, J, Pieczonka, A, Uyttebroeck, A, Lazic, J, Loeffen, J, Buechner, J, Niggli, F, Csoka, M, Krivan, G, Palma, J, Burke, G, Beishuizen, A, Koeppen, K, Mueller, S, Herbrueggen, H, Woessmann, W, Zimmermann, M, Balduzzi, A, and Pillon, M
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Outcome analysis ,CHILDHOOD ,Hematopoietic stem cell transplantation ,ACUTE-LYMPHOBLASTIC-LEUKEMIA ,Article ,refractory and relapsed non-Hodgkin lymphoma ,03 medical and health sciences ,RETROSPECTIVE ANALYSIS ,0302 clinical medicine ,PROGNOSTIC-FACTORS ,Refractory ,immune system diseases ,Internal medicine ,hemic and lymphatic diseases ,medicine ,Overall survival ,stem cell transplant ,ALLOGENEIC TRANSPLANTATION ,RITUXIMAB ,Anaplastic large-cell lymphoma ,RC254-282 ,Science & Technology ,business.industry ,Disease progression ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,B-CELL LYMPHOMA ,Children and adolescent ,medicine.disease ,3. Good health ,Lymphoma ,Leukemia ,HIGH-RISK ,children and adolescents ,030220 oncology & carcinogenesis ,TRIAL ,BURKITT-LYMPHOMA ,business ,Life Sciences & Biomedicine ,030215 immunology - Abstract
Despite poor survival, controversies remain in the treatment for refractory or relapsed pediatric non-Hodgkin lymphoma (r/r NHL). The current project aimed to collect international experience on the re-induction treatment of r/r NHL, hematopoietic stem cell transplantation (HSCT), risk factors associated with outcome, and to suggest treatment recommendations. Inclusion criteria were (i) refractory disease, disease progression or relapse of any NHL subtype except anaplastic large cell lymphoma, (ii) age <, 18 years at initial diagnosis, (iii) diagnosis in/after January 2000. Data from 639 eligible patients were evaluable. The eight-year probability of overall survival was 34 ± 2% with highly significant differences according to NHL subtypes: 28 ± 3% for 254 Burkitt lymphoma/leukemia, 50 ± 6% for 98 diffuse large B-cell lymphomas, 57 ± 8% for 41 primary mediastinal large B-cell lymphomas, 27 ± 3% for 177 T-lymphoblastic lymphomas, 52 ± 10% for 34 precursor-B-cell lymphoblastic lymphomas and 30 ± 9% for 35 patients with rare NHL subtypes. Subtype-specific factors associated with survival and treatment recommendations are suggested. There were no survivors without HSCT, except in few very small subgroups. Conclusions: There is an urgent need to further improve survival in r/r NHL. The current study provides the largest real-world series, which underlines the role of HSCT and suggests treatment recommendations.
- Published
- 2021